Hemab Therapeutics Holdings, Inc. (COAG)
COAGNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$40.86
+1.48 (+3.76%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.91bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $23.00 to $55.42
- Average volume
- –
- Previous close
- $39.38
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $64.00, +56.6% from here
Earnings
next estimate $-0.5900Next report
Mar 2026
–
Jun 2026
-27.0%
Sep 2026
-13.7%
estimate reported, and the surprise
News
8 latest- Hemab (COAG) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Hemab Therapeutics (COAG) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Hemab Begins Pivotal Study Of Potential Preventive Treatment For Glanzmann Thrombasthenia RTTNews · 6 days ago
- Rodman & Renshaw Initiates Coverage of Hemab Therapeutics Holdings with BuyFintel · Oct 12, 2026
- Hemab Doses First Participant In Phase 1 HMB-003 Trial For Heavy Menstrual Bleeding RTTNews · Sep 17, 2026
- Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG RTTNews · Aug 14, 2026
- Hemab Therapeutics Q2 Net Loss Widens; Plans To Initiate Phase 3 Trial Of Sutacimig In H2 2026 RTTNews · Aug 12, 2026
- Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX RTTNews · Aug 7, 2026
The company
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- www.hemab.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.